comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 02:27:57 - browse：455

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： The Karikó problem: Lessons for funding basic research

leisure time

WSS

Experts study whether long Covid risk adds up with each reinfection

6 solutions to address cancer drug shortages and others

Childhood vaccination ad campaign launches in the U.K.

Using force crossed my mind when examining a defiant young patient

Nobel honors Karikó and Weissman's enduring partnership

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

knowledge

comprehensive

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CDC panel: People 65 and older should get a Covid spring booster shot

At least 13 dead in Texas as scorching temps continue

Stop Congress from blocking public access to science

Anesthesiologist group: stop taking Ozempic before surgery

Lawsuit highlights wrinkle for disputes over surprise medical bills

How to save PrEP access — and even expand it

Stop Congress from blocking public access to science

Affirmative action in medical school literally saved lives

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

entertainment

CDC panel: People 65 and older should get a Covid spring booster shot

European officials brace for rough respiratory virus season

The Karikó problem: Lessons for funding basic research

With Roe v Wade overturned, abortion providers work to adapt

Congress extends some pandemic preparedness programs

The biotech scorecard for Q4: 16 stock

explore

leisure time

knowledge

focus